Limited (NYSE:VNRX) CEO Reynolds speaks to Proactive at the MicroCap Conference in New York.
Reynolds commented on recent preliminary data from a prospective study on Volition's Nu.Q™ assays to diagnose men with high-grade prostate cancer.
He says If these results are validated in larger trials, they will present a potentially significant new market opportunity
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...
FOR OUR FULL DISCLAIMER CLICK HERE